Outcome of COVID-19 Patients After Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome
Study Details
Study Description
Brief Summary
This study aims to investigate outcomes and predictors of outcome after extracorporeal membrane oxygenation (ECMO) therapy for severe acute respiratory syndrome (ARDS) in COVID-19 patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
We evaluated the outcome of adult patients with coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome (ARDS) requiring the use of extracorporeal membrane oxygenation (ECMO).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| COVID-19 positive patients
|
Device: Extracorporeal membrane oxygenation
Veno-venous or veno-arterial extracorporeal oxygenation
|
Outcome Measures
Primary Outcome Measures
- In-hospital mortality [Immediately after the intervention/procedure/surgery]
All-cause mortality
Secondary Outcome Measures
- Death on ECMO [During the intervention/procedure/surgery]
Death during ECMO therapy
- Stroke [Immediately after the intervention/procedure/surgery]
Stroke was defined as any focal or global neurological syndrome caused by ischemia and/or hemorrhage not resolving within 24 hours.
- Blood stream infection [Immediately after the intervention/procedure/surgery]
Blood stream infection detected on blood cultures
- Lung complications requiring surgical treatment [Immediately after the intervention/procedure/surgery]
Pneuthorax, pneumonia and/or abscess requiring surgical treatment
- Blood transfusion [Immediately after the intervention/procedure/surgery]
Transfusion of red blood cells
- Acute kidney injury [Immediately after the intervention/procedure/surgery]
Acute renal failure according to the Kidney Disease: Improving Global Outcomes classification (KDIGO) criteria
- Duration of mechanical ventilation [During index hospital stay follow-up until 1 year after ECMO initiation]
Duration of mechanical ventilation
- Deep vein thrombosis [Immediately after the intervention/procedure/surgery]
Thrombosis of lower limb deep venous system
- Pulmonary embolism [Immediately after the intervention/procedure/surgery]
Pulmonary embolism
- Length of intensive care unit stay [Immediately after the intervention/procedure/surgery]
Length of stay in the intensive care unit
- Length of hospital stay [Immediately after the intervention/procedure/surgery]
Length of hospital stay
- Death after hospital discharge [Up to 6 months]
All-cause death
Eligibility Criteria
Criteria
Inclusion Criteria:
- PCR-confirmed or suspected COVID-19 infection with ARDS who require any ECMO therapy
Exclusion Criteria:
- None
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Helsinki University Hospital | Helsinki | Finland | ||
| 2 | University Hospital Jean Minjoz | Besançon | France | ||
| 3 | Nancy University Hospital | Nancy | France | ||
| 4 | Henri Mondon Unoversity Hospital | Paris | France | ||
| 5 | Robert Debré University Hospital | Reims | France | ||
| 6 | Hamburg University Heart Center | Hamburg | Germany | ||
| 7 | Münster University Hospital | Münster | Germany | ||
| 8 | S. Orsola Hospital | Bologna | Italy | ||
| 9 | Lecco Hospital | Lecco | Italy | ||
| 10 | Karolinska University Hospital | Stockholm | Sweden | ||
| 11 | University Hospitals of Leicester | Leicester | United Kingdom |
Sponsors and Collaborators
- Helsinki University Central Hospital
Investigators
- Principal Investigator: Fausto Biancari, Professor, Helsinki University Central Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- COVID-19 ECMO